NLS Pharmaceutics (NLSP) Prices 322.58K Share Offering at $3.10/sh

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the pricing of a private placement offering consisting of the issuance and sale of up to 322,580 common shares only, par value CHF 0.80 per share, at a purchase price of $3.10 per common share, for aggregate gross proceeds of up to $1.0 million, subject to shareholder approval. The initial closing of the offering in the amount of $500,000 is expected to occur on or before January 10, 2025, and the subsequent closing of $500,000 may occur, at the election of the purchaser, within 15 days following the Company meeting certain conditions, including the receipt of shareholder approval and the Company's common shares trading for at least ten consecutive trading days above the purchase price of $3.10 which corresponds to an approx. 15% premium.

The Company intends to use the net proceeds from the offering for general corporate purposes.

The securities described above were offered pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Citi raises Atlassian price target to $225, maintains Buy rating
• Truist Securities Reiterates Hold Rating on Cousins Properties (CUZ)
• Rosenblatt Starts DoorDash Inc. (DASH) at Buy